Track topics on Twitter Track topics that are important to you
IXICO Plc (LON:IXI) said its TrialTracker technology will be used in a phase II clinical trial of a treatment for people with mild cognitive impairment caused by Alzheimer's disease. The digital platform will be used collate both positron emission tomography (PET) and MRI scans from centres across Europe. This data will be then assessed using IXICO's image analysis system, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in Alzheimer's patients. The trial is being run by Araclon Biotech and is designed to establish the dosage regimen, as well as confirm the safety and tolerability data obtained in phase I. IXICO chief executive Giulio Cerroni said: "We are delighted to be working with Araclon which continues our success in providing our customers with a solution that spans both PET and MR imaging services. “It is a great example of IXICO's growing value to the biopharmaceutical industry and reinforces our confidence in revenue growth this financial year." WATCH: Proactive's Andrew Scott talks to IXICO chief
Original Article: IXICO PLC technology to be used in Alzheimer's clinical trialNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...